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Introduction {#sec1-1}
============

Traumatic spinal cord injury (SCI) is one of the major causes of death and disabilities among all traumas. The reported incidence of SCI ranges from 9.2 to 246 cases per million (Jazayeri et al., 2015). Between 1993 and 2012, the incidence of acute traumatic SCI in the United States remained relatively stable; however, the total number of cases increased (Jain et al., 2015). To date, much effort has been made to evaluate the severity and the potential of recovery in patients with traumatic SCI; however, a reliable method for evaluating the severity and predicting the outcome following traumatic SCI, especially in the acute stages, has still not been achieved (Krishna et al., 2014; Silva et al., 2014). The current evaluation of traumatic SCI severity is still predominantly limited to neurological evaluation and imaging studies (Cheran et al., 2011; Pouw et al., 2014; Yokobori et al., 2015), which are often imprecise due to the unstable conditions of patients (such as the phenomenon of spinal shock) and the artifacts of metal implants after spinal operations. The limitation of current evaluation methods is also an obstacle for the development of new treatments for SCI patients (Hulme et al., 2017). Therefore, it would be beneficial and necessary to supplement current methods of evaluation with chemical biomarkers that reliably quantify traumatic SCI severity.

Tau protein is a microtubule-associated protein that is primarily localized in neurons (Breuzard et al., 2013). Tau protein has been shown to be a promising biomarker for axonal injury, because this protein binds to axonal microtubules and forms axonal microtubule bundles (Caprelli et al., 2017). Numerous studies have reported that tau protein concentrations in cerebrospinal fluid (CSF) and serum can serve as a biological marker for injury severity of the central nervous system, such as in traumatic brain injury (Liliang et al., 2010a, b; Magnoni et al., 2012), cerebral stroke (Bitsch et al., 2002; Wunderlich et al., 2006), Alzheimer's disease (Lewczuk et al., 2004; Tatebe et al., 2017; Mukaetova-Ladinska et al., 2018), and other central nervous system diseases (Brettschneider et al., 2005; Buongiorno et al., 2011). However, only one previous study has evaluated the relationship between tau protein levels and injury severity in traumatic SCI (Yokobori et al., 2015). Following traumatic SCI, neuronal cell death at the injury site is likely to cause a release of intracellular microtubule binding proteins, such as tau, into the extracellular space, where they are transported by convective bulk flow to CSF and peripheral blood. Recently, only one study in dogs with intervertebral disc herniation has reported that CSF tau levels were positively associated with the severity of spinal cord damage and may serve as a biomarker for severity of intervertebral disc herniation (Roerig et al., 2013).

This study attempted to measure tau protein levels in serum and CSF in rats with traumatic SCI. Our aims were to determine whether: (1) tau protein is detectable in serum and CSF samples of traumatic SCI, and (2) the tau protein level reflects the severity of the injury.

Materials and Methods {#sec1-2}
=====================

Animals {#sec2-1}
-------

One-hundred sixty female Sprague-Dawley rats, aged 8--9 months and weighing 230--280 g, were purchased from Beijing Experimental Animal Center of China (animal license No. SYXK (Jing) 2015-0046). All rats were housed in a climate-controlled barrier facility with 12-hour light/dark cycles at 24 ± 2°C, and allowed free access to food and water for a period of at least 1 week prior to the experimental procedures. All protocols were reviewed and approved by the Ethics Committee of Southwest Hospital, China (approval No. SWH20160126) on August 22, 2016. All experiments were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 80-23, revised 1996).

All rats were randomly and equally divided into four groups: sham group, mild SCI group, moderate SCI group and severe SCI group. Each group was further subdivided according to eight time points (1, 6, 12, 24 hours, 3, 7, 14 and 28 days after operation) to collect CSF and peripheral blood samples (*n* = 5 for each subgroup at each time point).

Group assignment and model establishment {#sec2-2}
----------------------------------------

The graded contusion models of SCI were performed using the NYU-MASCIS (New York University-Multicenter Animal Spinal Cord Injury Study) impactor according to previous methods (Agrawal et al., 2010). Briefly, rats were anesthetized *via* intraperitoneal injection of 10% chloralhydrate (3.0 mL/kg), and the vertebral column of the rats was exposed. A laminectomy was performed at the T8 level to expose the cord. A contusion lesion was made with the NYU-MASCIS impactor by dropping a 10 g rod from heights of 12.5 mm (mild SCI group), 25 mm (moderate SCI group) and 50 mm (severe SCI group) upon the exposed dorsal surface of the spinal cord. Rats in the sham group received laminectomy only. Paralysis of the lower limbs was observed along with tail swinging and spasms. These responses confirmed successful establishment of the model. After operation, rats were placed back into their cages with heating pads, and were closely observed until they were conscious. As a prophylactic for infections, penicillin (200,000 unit/animal/d) was subcutaneously given for 3 consecutive days after operation. Saline was subcutaneously injected immediately after lesioning and then daily for 7 days. Food and water were provided ad libitum. Post-operative care included manual expression of bladders twice a day until a reflex pattern of emptying the bladder was established.

Behavioral scores {#sec2-3}
-----------------

Locomotor functions of all rats were assessed using the Basso, Beattie, and Bresnahan locomotor rating scale (Basso et al., 1995), a 21-point scale to assess and analyze the hind limb movements of a rat in an open field, at 1, 6, 12, 24 hours, and 3, 7, 14 and 28 days after operation. The Basso, Beattie, Bresnahan scale ranges from 0 to 21, where 0 = complete paralysis and 21 = normal. Two investigators who were blinded to treatment assignment assessed the motor function of the rats at each time point.

Sample collection {#sec2-4}
-----------------

CSF and peripheral blood samples were immediately collected from all four groups at each time point while the rats were terminally anesthetized using an overdose of 10% chloralhydrate. CSF was collected from the cisterna magna as described previously (Shapiro et al., 2012). The 27 G needle syringe was inserted into the cisterna magna through the occipital membrane, and approximately 50 μL of CSF was collected. CSF samples were centrifuged at 2500 r/min at −4°C for 15 minutes to remove cellular debris. Immediately after CSF collection, 3 mL of blood was collected by cardiac puncture as described previously (Kim et al., 2014; Zhang et al., 2016). To harvest cell-free serum, the blood samples were drawn into a tube containing clot activator. After standing upright at 37°C for 30 minutes, the blood samples were centrifuged at 1500 r/min and 4°C for 15 minutes and the supernatant was collected as the serum component. The serum component and CSF were immediately frozen in liquid nitrogen and stored at −80°C until further testing.

Enzyme-linked immunosorbent assay (ELISA) {#sec2-5}
-----------------------------------------

Concentration of serum and CSF tau protein was measured using the commercial Rat pτ (phospho-Tau protein) ELISA kit (BioSource, Camarillo, CA, USA) according to the manufacturer's instructions. The minimum detectable dose of tau protein was 12 pg/mL. The detection methods were as follows: standards or test samples were added to the wells, incubated and washed to remove unbound proteins. An anti-tau-horseradish peroxidase-conjugated detector antibody was then added, incubated and unbound conjugate was washed away. An enzymatic reaction was produced through the addition of 3,3′,5′-tetramethylbenzidine substrate, which was catalyzed by horseradish peroxidase generating a blue color product that changes to yellow after adding acidic stop solution. The absorbance value was measured at 450 nm using a microplate reader (Thermo Fisher Scientific, Waltham, MA, USA). The concentration of tau in the samples was then determined by comparing the optical density of the samples to the standard curve.

Statistical analysis {#sec2-6}
--------------------

Data, expressed as the mean ± SD, were analyzed with SPSS 19.0 software (IBM, Armonk, NY, USA). Results were evaluated by one-way analysis of variance followed by Bonferroni's *post hoc* test. The relationship between variables was determined by the Spearman or Pearson correlation coefficient method. A value of *P* \< 0.05 was considered statistically significant.

Results {#sec1-3}
=======

Tau protein levels in serum and CSF {#sec2-7}
-----------------------------------

As shown in **[Figure 1](#F1){ref-type="fig"}**, the tau protein level in serum and CSF was slightly increased in the sham group at 12 hours after SCI compared with 1 hour after SCI. However, there was no significant difference in comparison with the rest of the time points. In all SCI rats, the levels of serum and CSF tau protein were increased at 1 hour to 6 hours after SCI, reached a peak at 12 hours, and then slowly decreased. However, tau protein levels in serum and CSF were relatively high for a period both in the moderate and severe SCI groups. Significant correlations were detected between CSF tau protein levels and serum tau levels at each time point in SCI rats (**[Table 1](#T1){ref-type="table"}**).

![Tau protein levels in serum and cerebrospinal fluid of rats following SCI.\
(A) Serum tau protein levels; (B) cerebrospinal fluid tau protein levels. \**P* \< 0.05, *vs*. sham group; \#*P* \< 0.05, *vs*. mild SCI group; †*P* \< 0.05, *vs*. moderate SCI group. Data are expressed as the mean ± SD (*n* = 5; one-way analysis of variance followed by Bonferroni's *post hoc* test). SCI: Spinal cord injury; h: hour(s); d: days.](NRR-14-896-g002){#F1}

###### 

Correlation of tau protein levels (pg/mL) in cerebrospinal fluid and serum in SCI rats (Pearson correlation analysis)

        1 hour    6 hours   12 hours   24 hours   3 days    7 days    14 days   28 days
  ----- --------- --------- ---------- ---------- --------- --------- --------- ---------
  *r*   0.83      0.97      0.98       0.98       0.96      0.81      0.77      0.51
  *P*   \< 0.01   \< 0.01   \< 0.01    \< 0.01    \< 0.01   \< 0.01   \< 0.01   0.02

The data are analyzed from the four groups (sham group, mild SCI group, moderate SCI group and severe SCI group, *n* = 20). SCI: Spinal cord injury.

Basso, Beattie, and Bresnahan locomotor rating scale scores {#sec2-8}
-----------------------------------------------------------

SCI caused complete paralysis of both lower extremities in all rats 12 hours post surgery, with a Basso, Beattie, and Bresnahan locomotor rating scale score of 0--1. Over the 4-week period, a gradual recovery was observed in all SCI groups (**[Figure 2](#F2){ref-type="fig"}**). Significant motor functional improvement was detected in the mild SCI group compared with moderate and severe SCI groups at 24 hours following SCI (*P* \< 0.05). The Basso, Beattie, and Bresnahan locomotor rating scale scores were negatively correlated with SCI severity at 24 hours, 3, 7, 14 and 28 days after SCI (**[Table 2](#T2){ref-type="table"}**).

![Temporal changes in BBB scores of rats following SCI.\
(A) Changes of BBB score over time; (B) Comparison of BBB score among groups. \**P* \< 0.05, *vs*. sham group; \#*P* \< 0.05, *vs*. mild SCI group; †*P* \< 0.05, *vs*. moderate SCI group. Data are expressed as the mean ± SD (*n* = 5; one-way analysis of variance followed by Bonferroni's *post hoc* test). BBB: Basso, Beattie, and Bresnahan locomotor rating scale; SCI: spinal cord injury; h: hour(s); d: days.](NRR-14-896-g003){#F2}

###### 

Correlation between SCI severity (mild, moderate, severe) and BBB scores (Spearman correlation analysis)

           1 hour   6 hours   12 hours   24 hours   3 days    7 days    14 days   28 days
  -------- -------- --------- ---------- ---------- --------- --------- --------- ---------
  *r~s~*   --0.41   --0.45    --0.46     --0.83     --0.89    --0.91    --0.97    --0.97
  *P*      0.13     0.07      0.13       \< 0.01    \< 0.01   \< 0.01   \< 0.01   \< 0.01

Two variables of the correlation analysis were: Basso, Beattie, and Bresnahan locomotor rating scale (BBB) scores and SCI severity (sham = 1; mild = 2; moderate = 3; severe = 4), respectively. All groups were involved in the analysis (*n* = 20).

Correlation of tau protein levels and SCI severity {#sec2-9}
--------------------------------------------------

A statistically significant, negative linear correlation was found between the concentration of serum tau protein and SCI severity at each time point; the same relationship was also found between CSF tau protein level and SCI severity (**[Table 3](#T3){ref-type="table"}**).

###### 

Correlation between tau protein levels and SCI severity (mild, moderate, severe; Spearman correlation analysis)

                                  1 hour    6 hours   12 hours   24 hours   3 days    7 days    14 days   28 days
  --------------------- --------- --------- --------- ---------- ---------- --------- --------- --------- ---------
  Serum                 *r~s~*    0.92      0.97      0.97       0.97       0.89      0.86      0.83      0.78
  *P*                   \< 0.01   \< 0.01   \< 0.01   \< 0.01    \< 0.01    \< 0.01   \< 0.01   \< 0.01   
  Cerebrospinal fluid   *r~s~*    0.87      0.97      0.97       0.97       0.92      0.93      0.87      0.78
  *P*                   \< 0.01   \< 0.01   \< 0.01   \< 0.01    \< 0.01    \< 0.01   \< 0.01   \< 0.01   

Two variables of the correlation analysis were: Basso, Beattie, and Bresnahan locomotor rating scale score and SCI severity (sham = 1; mild = 2; moderate = 3; severe = 4), respectively. All groups were involved in the analysis (*n* = 20). SCI: Spinal cord injury.

Correlation of tau protein levels and Basso, Beattie, and Bresnahan locomotor rating scale scores {#sec2-10}
-------------------------------------------------------------------------------------------------

The concentrations of serum tau protein were negatively correlated with the Basso, Beattie, and Bresnahan locomotor rating scale scores at each time point except 1, 6 and 12 hours, and the same relationship was also found between the CSF tau protein level and SCI severity (**[Table 4](#T4){ref-type="table"}**). We also analyzed the relationship between the peak concentration of serum and CSF tau protein at 12 hours and the Basso, Beattie, and Bresnahan locomotor rating scale scores at 28 days. Results showed a significant negative correlation in CSF tau protein levels with 28 days' Basso, Beattie, and Bresnahan locomotor rating scale scores (*r* = −0.95, *P* \< 0.01); similar results also were found with serum tau protein level (*r* = −0.94, *P* \< 0.01) (**[Figure 3](#F3){ref-type="fig"}**).

![Relationship between peak concentration of tau protein at 12 hours and BBB score at 28 days post injury.\
All groups were involved in the correlation analysis (*n* = 20). (A, B) Pearson correlation analysis showed a significant negative correlation between serum tau protein levels and 28 days' BBB score (A), and between CSF tau protein level and 28 days' BBB score (B). BBB: Basso, Beattie, and Bresnahan locomotor rating scale; CSF: cerebrospinal fluid.](NRR-14-896-g004){#F3}

###### 

Correlation between tau protein levels (pg/mL) and Basso, Beattie, and Bresnahan rating scale score (Pearson correlation analysis)

                               1 hour   6 hours   12 hours   24 hours   3 days    7 days    14 days   28 days
  --------------------- ------ -------- --------- ---------- ---------- --------- --------- --------- ---------
  Serum                 *r*    --0.13   --0.25    --0.55     --0.81     --0.87    --0.84    --0.82    --0.85
  *P*                   0.95   0.78     0.13      0.02       \< 0.01    \< 0.01   \< 0.01   \< 0.01   
  Cerebrospinal fluid   *r*    --0.15   --0.31    --0.69     --0.82     --0.81    --0.85    --0.81    --0.71
  *P*                   0.87   0.71     0.03      \< 0.01    \< 0.01    \< 0.01   \< 0.01   \< 0.01   

All groups were involved in the analysis (*n* = 20).

Discussion {#sec1-4}
==========

In this study, a standardized rat injury model with NYU-MASCIS impactor was used to evaluate the relationship between tau protein level and SCI severity. This allowed us to define the severity of injury (mild, moderate, and severe) as described previously (Agrawal et al., 2010). A significant positive correlation was found between tau protein levels (both in CSF and serum) and measures of severity in rats with traumatic SCI.

The pathophysiology of traumatic SCI includes primary and secondary injuries to the spinal cord (Zhang et al., 2018). The primary injury is mainly due to the mechanical force to the spinal cord, which results in the disruption of axons. The injury then leads to a cascade of biological events, described as ''secondary injury'', which occurs over the course of minutes to weeks, and leads to further neurological damage (Wen et al., 2016; Rong et al., 2017; Fan et al., 2018). The severity of the injury is thought to be largely dependent on the extent of neuronal damage, including the primary and second injuries to the spinal cord. The microtubule-associated protein tau is a cytoskeletal protein expressed primarily in the central nervous system, where it stabilizes microtubules and regulates microtubule assemblies (Caprelli et al., 2017; Guo et al., 2017; Josephs, 2017; Sotiropoulos et al., 2017). Therefore, this investigation was designed to evaluate whether tau protein level in CSF or serum reflects the severity of traumatic SCI.

To our knowledge, this is the first report investigating the dynamic changes of the tau protein level in a traumatic SCI model. In our study, we found that tau protein level (both in serum and CSF) was increased significantly after SCI. The peak concentration occurred at 12 hours and remained at a relatively high level for 3 days. Similarly, in a model of rat traumatic brain injury, the tau protein level was significantly increased after injury, and peaked as early as 1 hour (Liliang et al., 2010b). Consistent with many other studies of biomarkers (Wang et al., 2016; Wu et al., 2016), our results also showed that the tau protein level in CSF was significantly higher than that in serum; furthermore, the level of serum tau protein was positively correlated with CSF tau protein level.

The Basso, Beattie, and Bresnahan locomotor rating scale has been widely used to evaluate the behavioral outcome after SCI (Duan et al., 2018; Fu et al., 2018; Ko et al., 2018). In our study, behavioral outcomes measured by Basso, Beattie, Bresnahan score were similar to those in previous studies (Yahata et al., 2016; Gu et al., 2017; Rink et al., 2018). Mean Basso, Beattie, and Bresnahan locomotor rating scale scores showed a significant difference between different severity groups at the same time point after SCI, and Basso, Beattie, Bresnahan scores were negatively correlated with SCI severity at 7, 14 and 28 days after SCI. Furthermore, a negative correlation was found between the levels of tau protein and Basso, Beattie, and Bresnahan locomotor rating scale scores after traumatic SCI. Thus, a higher tau protein concentration in serum or CSF at 12 hours suggested worse locomotor function outcome at 28 days. In the current study, the tau protein level both in serum and CSF was remarkably correlated with SCI severity at 28 days after injury. This association would be helpful to evaluate the severity of SCI, especially in the early phase of injury. Similarly, in a study in dogs with SCI by intervertebral disc herniation, CSF tau protein concentrations showed significant differences between different severities of intervertebral disc herniation (Roerig et al., 2013).

Neuronal cell injury or death is likely to cause a release of intracellular microtubule binding proteins, such as tau, into the extracellular space, where they are transported by convective bulk flow to CSF (Segal, 1993; Zetterberg, 2017). Previous studies have reported that biomarkers, such as S100-β and serum microRNAs, may have potential to aid the evaluation or diagnosis of SCI (Cao et al., 2008; Hachisuka et al., 2014; Kuhle et al., 2015; Sabour et al., 2017; Tigchelaar et al., 2017). However, because these markers are not involved in structural components of neurons, they do not directly reflect the functional status of the cells. Further, because of their low specificity in patients with multiple traumas, these markers seem to be inadequate for diagnosis and outcome prediction (Ydens et al., 2017).

In the present study, tau protein was identified both in serum and CSF as a promising biomarker for evaluating the severity of SCI in the acute phase. The levels of tau protein both in serum and CSF were higher with increasing severity of SCI. Although the tau protein level was lower in serum compared with CSF at the same time points, a positive correlation was found between them. When a neuron is severely injured, tau protein is released into the extracellular space through the damaged membrane (Lee et al., 2018). Because the blood-brain barrier was probably damaged at the same time of traumatic SCI, tau protein likely flowed into the blood as well (Caprelli et al., 2018). Tau protein directly reflects neuronal injury because tau protein is primarily localized in axons (Qi et al., 2016). Therefore, we believe that the tau protein level may be a perfect biomarker for evaluating the severity of SCI. Monitoring tau protein level in serum may have a profound use for the prediction of neuronal functional outcomes after SCI. As tau protein contributes to microtubule assembly and stabilization in axons, further research will focus on the possibility of using a microtubule stabilizer to prevent abnormal tau release from healthy neurons and to improve its function after traumatic SCI.

There were certain limitations to our study. First, although our study suggests that tau has potential as a biomarker of SCI, further studies in patients with varying degrees of SCI are needed. The use of such biomarkers in clinical trials may accelerate the development of novel therapeutic approaches of SCI. Second, it is worth mentioning that in recent years, immune cells have been shown to play an increasingly important role in the pathophysiology of brain and SCI (Feng et al., 2016; Barbagallo et al., 2017; Li et al., 2017). Recent studies have found that mice show a strong inflammatory response accompanied by activation of glial cells and involvement of necroptosis signaling following chronic ischemic injury (Yang et al., 2017; Cruz et al., 2018). Furthermore, inflammatory cytokines expression levels are markedly increased in brain ischemic injury (Xu et al., 2016; Chen et al., 2017). Further studies are needed to explore whether associations exist between immune cells and tau protein following central nervous system damage.

Taken together, there is clearly an urgent need to innovate more sensitive and reliable biomarkers in the acute stages of SCI, because successful management of SCI necessitates an appropriate diagnostic standard for the acute stages after injury. To our knowledge, this is the first study to investigate the relationship between tau protein level and injury severity in rats with traumatic SCI. Our preliminary data showed that tau protein level (both in serum and CSF) was positively correlated with the injury severity and negatively correlated with the locomotor outcome. Therefore, we suggest that tau protein level may be a perfect biomarker for evaluating the severity of SCI. Further studies in patients are warranted to increase the evidence for tau protein as an injury severity marker.
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